NASDAQ:GLUE Monte Rosa Therapeutics Q1 2025 Earnings Results & Report $10.12 +0.28 (+2.85%) Closing price 10/15/2026 04:00 PM EasternExtended Trading$10.15 +0.03 (+0.30%) As of 07:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Monte Rosa Therapeutics beat analyst expectations on both earnings and revenue in its Q1 2025 results, released May 8, 2025. The company reported EPS of $0.57 versus the -$0.24 consensus estimate, while revenue of $84.93 million topped the $13.57 million estimate by $71.36 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 8, 2025TimeBefore Market OpensConference Call7:00 AM ET Monte Rosa Therapeutics EPS ResultsActual EPS$0.57Consensus EPS -$0.24Beat/MissBeat by +$0.81One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersMonte Rosa Therapeutics Revenue ResultsActual Revenue$84.93 millionExpected Revenue$13.57 millionBeat/MissBeat by +$71.36 millionYoY Revenue GrowthN/AUpcoming EarningsMonte Rosa Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Monte Rosa Therapeutics Q1 2025 Earnings FAQ Did Monte Rosa Therapeutics beat earnings estimates for Q1 2025? Monte Rosa Therapeutics (NASDAQ:GLUE) reported earnings of $0.57 per share for Q1 2025, beating the consensus estimate of -$0.24. The report was announced on Thursday, May 8, 2025. What was Monte Rosa Therapeutics' revenue for Q1 2025? Monte Rosa Therapeutics reported revenue of $84.93 million for Q1 2025, against a consensus estimate of $13.57 million. When is Monte Rosa Therapeutics' next earnings date? Monte Rosa Therapeutics' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Monte Rosa Therapeutics on the company's earnings history page. Monte Rosa Therapeutics Earnings HeadlinesMonte Rosa Therapeutics (NASDAQ:GLUE) vs. Krystal Biotech (NASDAQ:KRYS) Head to Head Survey3 hours ago | americanbankingnews.comImmunityBio (NASDAQ:IBRX) versus Monte Rosa Therapeutics (NASDAQ:GLUE) Head-To-Head SurveyOctober 13 at 5:29 AM | americanbankingnews.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.October 16 at 1:00 AM | Weiss Ratings (Ad)Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk - SlideshowOctober 5, 2026 | seekingalpha.comPiper Sandler Remains a Buy on Monte Rosa Therapeutics (GLUE)October 4, 2026 | theglobeandmail.comMonte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | globenewswire.comSee More Monte Rosa Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Monte Rosa Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Monte Rosa Therapeutics and other key companies, straight to your email. Email Address About Monte Rosa TherapeuticsMonte Rosa Therapeutics (NASDAQ:GLUE) is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses its proprietary molecular glue degrader platform to identify small molecules that recruit targeted proteins to the cell’s natural protein-disposal machinery, potentially addressing proteins that have been difficult to treat with conventional drugs. Monte Rosa’s pipeline is centered primarily on autoimmune and inflammatory diseases, as well as other serious conditions. Its lead programs include MRT-6160, an oral molecular glue degrader designed to target VAV1, a protein involved in immune-cell signaling, and additional discovery and development programs aimed at other disease-relevant targets. The company’s platform is intended to support the development of medicines across multiple therapeutic areas. Founded in 2018 and headquartered in Boston, Massachusetts, Monte Rosa conducts research and clinical development with the goal of serving patients globally. The company became a publicly traded company in 2021 and is led by a team of biotechnology and drug-development professionals.View Monte Rosa Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
